{"title":"Metastasis Targeted Therapies in Renal Cell Cancer","authors":"K. Narter, B. Özveren","doi":"10.4274/uob.962","DOIUrl":"https://doi.org/10.4274/uob.962","url":null,"abstract":"","PeriodicalId":40816,"journal":{"name":"Uroonkoloji Bulteni-Bulletin of Urooncology","volume":"17 1","pages":"26-32"},"PeriodicalIF":0.2,"publicationDate":"2018-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70979486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A Rare Side Effect of Intravesical Bacillus Calmette-Guérin Therapy: Reactive Arthritis","authors":"Bahattin Kizilgok, V. Izol, E. Erken, M. Tansug","doi":"10.4274/UOB.915","DOIUrl":"https://doi.org/10.4274/UOB.915","url":null,"abstract":"","PeriodicalId":40816,"journal":{"name":"Uroonkoloji Bulteni-Bulletin of Urooncology","volume":"17 1","pages":"33-35"},"PeriodicalIF":0.2,"publicationDate":"2018-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48685658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ad dress for Cor res pon den ce: Taha Numan Yıkılmaz MD, University of Health Sciences, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Clinic of Urology, Ankara, Turkey Phone: +90 312 336 09 09 E-mail: numanyikilmaz@gmail.com ORCID-ID: orcid.org/0000-0001-8410-2474 Re cei ved: 02.10.2017 Ac cep ted: 13.12.2017 Objective: We aimed to compare the oncologic and functional outcomes of patients who underwent subcapsular or total orchiectomy for surgical castration in prostate cancer. Materials and Methods: We studied 65 patients who underwent total or subcapsular orchiectomy with a diagnosis of prostate cancer between April 2014 and May 2017. At postoperative 3-month follow-up, prostate specific antigen (PSA) and total testosterone levels were measured and patients were asked about their psychological status due to organ loss. Results were compared between the groups. Results: Sixty-five patients were evaluable: 23 had subcapsular and 42 had total orchiectomy. The mean age of the cases was 71.4 (60-83) years, the mean PSA level was 45.4 ng/dL (4-3800 ng/dL), and 41 cases had metastatic foci. There was no significant difference between the complication rates of the groups, but duration of the operation was significantly shorter in the subcapsular orchiectomy group. The two groups had similar mean PSA and testosterone levels at postoperative 3 months, but significantly more patients with total orchiectomy reported psychological problems due to organ loss. Conclusion: Subcapsular orchiectomy should be preferred for surgical castration because of the short duration of operation and the advantage of organ presence within the scrotal sac after surgery. In terms of oncologic outcomes, subcapsular orchiectomy shows no difference from total orchiectomy and is a safe alternative.
{"title":"Comparison of Subcapsular and Total Orchiectomy in Patients with Prostate Cancer","authors":"T. N. Yıkılmaz, E. Öztürk, N. Hamidi, H. Başar","doi":"10.4274/uob.925","DOIUrl":"https://doi.org/10.4274/uob.925","url":null,"abstract":"Ad dress for Cor res pon den ce: Taha Numan Yıkılmaz MD, University of Health Sciences, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Clinic of Urology, Ankara, Turkey Phone: +90 312 336 09 09 E-mail: numanyikilmaz@gmail.com ORCID-ID: orcid.org/0000-0001-8410-2474 Re cei ved: 02.10.2017 Ac cep ted: 13.12.2017 Objective: We aimed to compare the oncologic and functional outcomes of patients who underwent subcapsular or total orchiectomy for surgical castration in prostate cancer. Materials and Methods: We studied 65 patients who underwent total or subcapsular orchiectomy with a diagnosis of prostate cancer between April 2014 and May 2017. At postoperative 3-month follow-up, prostate specific antigen (PSA) and total testosterone levels were measured and patients were asked about their psychological status due to organ loss. Results were compared between the groups. Results: Sixty-five patients were evaluable: 23 had subcapsular and 42 had total orchiectomy. The mean age of the cases was 71.4 (60-83) years, the mean PSA level was 45.4 ng/dL (4-3800 ng/dL), and 41 cases had metastatic foci. There was no significant difference between the complication rates of the groups, but duration of the operation was significantly shorter in the subcapsular orchiectomy group. The two groups had similar mean PSA and testosterone levels at postoperative 3 months, but significantly more patients with total orchiectomy reported psychological problems due to organ loss. Conclusion: Subcapsular orchiectomy should be preferred for surgical castration because of the short duration of operation and the advantage of organ presence within the scrotal sac after surgery. In terms of oncologic outcomes, subcapsular orchiectomy shows no difference from total orchiectomy and is a safe alternative.","PeriodicalId":40816,"journal":{"name":"Uroonkoloji Bulteni-Bulletin of Urooncology","volume":"17 1","pages":"5-8"},"PeriodicalIF":0.2,"publicationDate":"2018-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70979235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Guragac, S. Yılmaz, Z. Demirer, H. C. Irkılata, Y. Kibar
{"title":"Prostate and Bladder Metastases of Malignant Melanoma: Case Report","authors":"A. Guragac, S. Yılmaz, Z. Demirer, H. C. Irkılata, Y. Kibar","doi":"10.4274/UOB.911","DOIUrl":"https://doi.org/10.4274/UOB.911","url":null,"abstract":"","PeriodicalId":40816,"journal":{"name":"Uroonkoloji Bulteni-Bulletin of Urooncology","volume":"17 1","pages":"36-38"},"PeriodicalIF":0.2,"publicationDate":"2018-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48219840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective: Prostate cancer is the most common malignancy in men and the second cause of cancer-related mortality. Prostate biopsy and the Gleason score guide treatment decisions in prostate cancer. Several studies have investigated the correlation between biopsy scores and radical prostatectomy specimen scores. We also evaluated the correlation of Gleason scores of these specimens in our patient series. Materials and Methods: We retrospectively reviewed the data of 468 men who were diagnosed with prostate cancer and underwent radical prostatectomy between 2008 and 2017. Patients’ age, prostate-specific antigen levels at diagnosis, and prostate biopsy and radical prostatectomy specimen Gleason scores were recorded. Upgrading and downgrading were defined as increase or decrease of Gleason score of radical prostate specimen compared to Gleason score of prostate biopsy. Results: A total of 442 men diagnosed with prostate cancer were included in the study. The mean age of the patients was 62.62±6.26 years (44-84 years) and mean prostate specific antigen level was 9.01±6.84 ng/mL (1.09-49 ng/mL). Prostate biopsy Gleason score was <7 in 335 (75.8%) men, 7 in 80 (18.1%) men, and >7 in 27 (6.1%) men. Radical prostatectomy specimen Gleason score was <7 in 267 (60.4%) men, 7 in 113 (25.5%) men and >7 in 62 (14%) men. Gleason correlation was highest in the 240 patients (71.6%) with score <7 and was lowest in the 31 (38.75%) patients with score =7. Conclusion: This study demonstrated that the discordance rate between Gleason scores of prostate biopsy and radical prostatectomy specimens was 35.7%.
{"title":"Gleason Score Correlation Between Prostate Biopsy and Radical Prostatectomy Specimens","authors":"E. Öztürk, T. N. Yıkılmaz","doi":"10.4274/UOB.921","DOIUrl":"https://doi.org/10.4274/UOB.921","url":null,"abstract":"Objective: Prostate cancer is the most common malignancy in men and the second cause of cancer-related mortality. Prostate biopsy and the Gleason score guide treatment decisions in prostate cancer. Several studies have investigated the correlation between biopsy scores and radical prostatectomy specimen scores. We also evaluated the correlation of Gleason scores of these specimens in our patient series. Materials and Methods: We retrospectively reviewed the data of 468 men who were diagnosed with prostate cancer and underwent radical prostatectomy between 2008 and 2017. Patients’ age, prostate-specific antigen levels at diagnosis, and prostate biopsy and radical prostatectomy specimen Gleason scores were recorded. Upgrading and downgrading were defined as increase or decrease of Gleason score of radical prostate specimen compared to Gleason score of prostate biopsy. Results: A total of 442 men diagnosed with prostate cancer were included in the study. The mean age of the patients was 62.62±6.26 years (44-84 years) and mean prostate specific antigen level was 9.01±6.84 ng/mL (1.09-49 ng/mL). Prostate biopsy Gleason score was <7 in 335 (75.8%) men, 7 in 80 (18.1%) men, and >7 in 27 (6.1%) men. Radical prostatectomy specimen Gleason score was <7 in 267 (60.4%) men, 7 in 113 (25.5%) men and >7 in 62 (14%) men. Gleason correlation was highest in the 240 patients (71.6%) with score <7 and was lowest in the 31 (38.75%) patients with score =7. Conclusion: This study demonstrated that the discordance rate between Gleason scores of prostate biopsy and radical prostatectomy specimens was 35.7%.","PeriodicalId":40816,"journal":{"name":"Uroonkoloji Bulteni-Bulletin of Urooncology","volume":"17 1","pages":"1-4"},"PeriodicalIF":0.2,"publicationDate":"2018-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70979140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S. Çelik, Ozan Bozkurt, H. Yıldız, O. Demir, B. Tuna, K. Yorukoglu, G. Aslan
{"title":"Predictive Value of Hormonal Evaluation Before Prostate Needle Biopsy on Prostate Cancer T Stage and Prognosis","authors":"S. Çelik, Ozan Bozkurt, H. Yıldız, O. Demir, B. Tuna, K. Yorukoglu, G. Aslan","doi":"10.4274/UOB.942","DOIUrl":"https://doi.org/10.4274/UOB.942","url":null,"abstract":"","PeriodicalId":40816,"journal":{"name":"Uroonkoloji Bulteni-Bulletin of Urooncology","volume":"17 1","pages":"9-13"},"PeriodicalIF":0.2,"publicationDate":"2018-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70979313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Determination of Six Transmembrane Protein of Prostate 2 Gene Expression and Intracellular Localization in Prostate Cancer","authors":"Bora Irer, O. Demir, A. Kefi, G. Aslan","doi":"10.4274/UOB.890","DOIUrl":"https://doi.org/10.4274/UOB.890","url":null,"abstract":"","PeriodicalId":40816,"journal":{"name":"Uroonkoloji Bulteni-Bulletin of Urooncology","volume":"16 1","pages":"112-118"},"PeriodicalIF":0.2,"publicationDate":"2017-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47248685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mesane kanserlerin %90’ından transizyonel hücreli (ürotelyal) karsinomlar sorumludur (1). Skuamöz hücreli karsinom ve adenokarsinoma daha az sıklıkla görülmektedir. Bu üç kanserin dışında kalan mesane tümörlerine nadiren rastlanmakla birlikte literatürde daha çok küçük hasta serilerine veya tek olguluk hasta sunumlarına rastlanmaktadır. Bu nadir tümörler az sıklıkla görülmelerine rağmen patolojik açıdan ürotelyal karsinomdan ayrımlarının yapılması gerekmektedir. Klinik seyirlerinin ve tedavi yaklaşımlarının ürotelyal karsinomdan farklılık göstermesi bu az rastlanan tümörleri ürolojik açıdan önemli hale getirmektedir. Bu tümörler klinik semptom olarak sıklıkla hematüri ile ortaya çıkarlar. İritatif ve obstrüktif semptomlarla da kendini gösteren tümörler vardır. Bu mesanede görülen nadir kitlelerden benign olanlar enflamatuvar miyofibroblastik tümör (İMT), postoperatif iğsi hücreli nodül (PSCN), sistitis sistika benzeri fibroepitelyal polip, leyomiyom, hemanjiyoma, nörofibroma, schwannoma, psödokarsinomatöz hiperplazi, soliter fibröz tümör ve inverted papillomadır. Malignite potansiyeli belirsiz olanlar ise paragangliyoma, granüler hücreli tümör ve perivasküler epiteloid hücreli tümördür. Bu derlemede mesanede nadir görülen benign ve malignite potansiyeli belirsiz tümörlerin belirgin klinikopatolojik özellikleri literatür gözden geçirilerek ortaya konulmuştur. Benign Tümörler
{"title":"Rare Benign and Uncertain Malignant Potential Tumors of Bladder: Review of the Literature","authors":"C. Yucel, M. Keskin","doi":"10.4274/UOB.673","DOIUrl":"https://doi.org/10.4274/UOB.673","url":null,"abstract":"Mesane kanserlerin %90’ından transizyonel hücreli (ürotelyal) karsinomlar sorumludur (1). Skuamöz hücreli karsinom ve adenokarsinoma daha az sıklıkla görülmektedir. Bu üç kanserin dışında kalan mesane tümörlerine nadiren rastlanmakla birlikte literatürde daha çok küçük hasta serilerine veya tek olguluk hasta sunumlarına rastlanmaktadır. Bu nadir tümörler az sıklıkla görülmelerine rağmen patolojik açıdan ürotelyal karsinomdan ayrımlarının yapılması gerekmektedir. Klinik seyirlerinin ve tedavi yaklaşımlarının ürotelyal karsinomdan farklılık göstermesi bu az rastlanan tümörleri ürolojik açıdan önemli hale getirmektedir. Bu tümörler klinik semptom olarak sıklıkla hematüri ile ortaya çıkarlar. İritatif ve obstrüktif semptomlarla da kendini gösteren tümörler vardır. Bu mesanede görülen nadir kitlelerden benign olanlar enflamatuvar miyofibroblastik tümör (İMT), postoperatif iğsi hücreli nodül (PSCN), sistitis sistika benzeri fibroepitelyal polip, leyomiyom, hemanjiyoma, nörofibroma, schwannoma, psödokarsinomatöz hiperplazi, soliter fibröz tümör ve inverted papillomadır. Malignite potansiyeli belirsiz olanlar ise paragangliyoma, granüler hücreli tümör ve perivasküler epiteloid hücreli tümördür. Bu derlemede mesanede nadir görülen benign ve malignite potansiyeli belirsiz tümörlerin belirgin klinikopatolojik özellikleri literatür gözden geçirilerek ortaya konulmuştur. Benign Tümörler","PeriodicalId":40816,"journal":{"name":"Uroonkoloji Bulteni-Bulletin of Urooncology","volume":"16 1","pages":"123-126"},"PeriodicalIF":0.2,"publicationDate":"2017-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70977514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ya z›fl ma Ad re si/Ad dress for Cor res pon den ce: Dr. Erdem Şen, Selçuk Üniversitesi Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Tıbbi Onkoloji Bilim Dalı, Konya, Türkiye Tel.: +90 332 606 05 05 E-mail: dr17erdem@mynet.com ORCID-ID: orcid.org/0000-0003-0748-1989 Ge liş Ta ri hi/Re cei ved: 16.08.2017 Ka bul Ta ri hi/Ac cep ted: 04.10.2017 Selçuk Üniversitesi Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Tıbbi Onkoloji Bilim Dalı, Konya, Türkiye Dr. Erdem Şen, Dr. İrem Öner, Dr. Özlem Ata Neutropenic Fever, Skin and Eye Toxicities Develops During Docetaxel Treatment in Metastatic Prostate Cancer: A Case Report Dosetaksel Tedavisi Sırasında Nötropenik Ateş, Deri ve Göz Toksisitesi Gelişen Metastatik Prostat Kanserli Bir Olgu Bulletin of Urooncology 2017;16:133-136 DO I: 10.4274/uob.908
关于Cor res pon的广告/广告连衣裙，Erdem Shan博士，土耳其科尼亚自治大学内科肿瘤研究所，电话：+90 332 606 05电子邮件：dr17erdem@mynet.comORCID-ID:ORCID.org/0000-0003-0748-1989 Ge lišTa ri hi/Re cei ved:16.08.2017 Ka ri hi/Ac cep ted:04.10.2017大理自治大学医学院内科Anabilism Dali，医学肿瘤学Dali，Konya，土耳其医生Erdem Shan，IremÖner，Özlem Ata中性粒细胞热，多西他赛治疗转移性前列腺癌症期间产生的皮肤和眼睛毒性：一份病例报告多西他塞尔医学订单Nötropenik Ateš，Deri和Göz Toksicity晚期转移性前列腺Kanserli A Olgu泌尿肿瘤学公报2017；16:133-136 DO I:10.4274/uob.908
{"title":"Neutropenic Fever, Skin and Eye Toxicities Develops During Docetaxel Treatment in Metastatic Prostate Cancer: A Case Report","authors":"E. Şen, İrem Öner, O. Ata","doi":"10.4274/UOB.908","DOIUrl":"https://doi.org/10.4274/UOB.908","url":null,"abstract":"Ya z›fl ma Ad re si/Ad dress for Cor res pon den ce: Dr. Erdem Şen, Selçuk Üniversitesi Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Tıbbi Onkoloji Bilim Dalı, Konya, Türkiye Tel.: +90 332 606 05 05 E-mail: dr17erdem@mynet.com ORCID-ID: orcid.org/0000-0003-0748-1989 Ge liş Ta ri hi/Re cei ved: 16.08.2017 Ka bul Ta ri hi/Ac cep ted: 04.10.2017 Selçuk Üniversitesi Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Tıbbi Onkoloji Bilim Dalı, Konya, Türkiye Dr. Erdem Şen, Dr. İrem Öner, Dr. Özlem Ata Neutropenic Fever, Skin and Eye Toxicities Develops During Docetaxel Treatment in Metastatic Prostate Cancer: A Case Report Dosetaksel Tedavisi Sırasında Nötropenik Ateş, Deri ve Göz Toksisitesi Gelişen Metastatik Prostat Kanserli Bir Olgu Bulletin of Urooncology 2017;16:133-136 DO I: 10.4274/uob.908","PeriodicalId":40816,"journal":{"name":"Uroonkoloji Bulteni-Bulletin of Urooncology","volume":"16 1","pages":"133-136"},"PeriodicalIF":0.2,"publicationDate":"2017-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70979326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Evaluation of the Relationship Between Duration of Smoking and Clinical and Pathologic Characteristics of Bladder Cancer at Diagnosis","authors":"Bora Irer, F. Dağ, G. Aslan","doi":"10.4274/uob.870","DOIUrl":"https://doi.org/10.4274/uob.870","url":null,"abstract":"","PeriodicalId":40816,"journal":{"name":"Uroonkoloji Bulteni-Bulletin of Urooncology","volume":"27 1","pages":"108-111"},"PeriodicalIF":0.2,"publicationDate":"2017-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70979285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：